Use of creatinine clearances to monitor the effect of low-dose dopamine in critically ill surgical patients.
BACKGROUND
Despite uncertain evidence of its efficacy, "low-dose dopamine" (2-5 microg/kg/min) has often been used to augment renal perfusion in critically ill surgical patients. The 2-h creatinine clearance (CC) has been shown to be a monitor of renal function in critically ill patients. We therefore studied the use of sequential CC determinations to monitor the effect of low-dose dopamine (LDD) in surgical intensive care unit (SICU) patients. We hypothesized that sequential CC measurements could demonstrate whether individual patients had positive responses in renal function to LDD.


METHODS
Data were prospectively collected for patients on LDD in a university SICU. CC were recorded for these patients immediately before and after the institution of LDD or before and after the cessation of LDD. APACHE II scores, gender, urine creatinine, age, blood pressure, heart rate, and urine output (UO) were also recorded for these patients; P < 0.05.


RESULTS
Twenty-four pairs of CC values were observed during the study. The mean APACHE II score for the patients was 15.1. In 10 cases after initiation of LDD, the mean CC increased from 52.5 +/- 23.7 ml/min to 68.1 +/- 33.8 ml/min (P = 0.056). UO also increased from 48.0 +/- 27 to 75.9 +/- 49 ml/h (NS). In 14 cases after discontinuation of LDD, CC decreased from 85.6 +/- 36.3 ml/min to 63.6 +/- 45.5 ml/min (P = 0.044) and UO decreased from 105.1 +/- 73.9 to 89.6 +/- 76.7 ml/h (NS). Overall, 13 of the 24 patients had a 25% change or more in CC upon initiation or cessation of LDD.


CONCLUSIONS
LDD institution increased CC in individual patients in the SICU population. Because using LDD in the absence of a discernable improvement in renal function is costly and may harbor risks, we recommend following CC in patients on LDD to determine which patients derive benefit from the intervention.
Eachempati
Soumitra R
SR
Department of Surgery, Weill Medical College of Cornell University, New York, New York, USA.
Reed
R Lawrence
RL
D018806:APACHE; D001794:Blood Pressure; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D003404:Creatinine / Q000652:urine*; D016638:Critical Illness; D004298:Dopamine / Q000008:administration & dosage*; D006339:Heart Rate; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000502:physiology; D009846:Oliguria / Q000188:drug therapy* / Q000652:urine; D011446:Prospective Studies; D014556:Urine
D002316:Cardiotonic Agents; D003404:Creatinine; D004298:Dopamine